What is the Evidence for Pharmaceutical Patient Assistance Programs?: A Systematic Review

Felder, Tisha M.; Palmer, Nynikka R.; Lal, Lincy S.; Mullen, Patricia Dolan

doi:10.1353/hpu.2011.0003

Cited by 43 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharma companies provided access initiatives for 57% of essential cancer medicines on the EML in 2017 (Cuomo & Mackey, 2018). However, evidence is limited on the implementation and impacts of such Patient Assistance Schemes’ clinical and cost‐effectiveness from a patient and healthcare system perspectives (Felder et al, 2011). Beyond access to medicines and the pharmaceutical sector, understanding the impact of all private sector initiatives will improve accountability of providers to patients.…”

Section: The “Messiness” Of Cancer Governancementioning

confidence: 99%

The global challenge of cancer governance

Lunt

2023

World Med & Health Policy

View full text Add to dashboard Cite

The global cancer statistics are stark, accounting for nearly 10 million deaths in 2020, around one in six of all deaths globally. The World Health Organization estimates that 70% of these cancer deaths occur in low‐ and middle‐income countries and cancer will continue to rise as a proportion of deaths in these settings. We may usefully characterize cancer as a “social mess,” a set of interrelated problems and other messes including poverty and social determinants of health. One part of cancer's “messiness” is the governance deficit around cancer burden and regional inequities This policy paper assesses the field of global oncology governance and the interplay of legal instruments, soft law, national developments, donor activities, as well as partnerships, networks, and coalitions. Cancer governance is central to tackling cancer inequalities. Continuing to probe the complexities of cancer governance requires attention to market mechanisms, international agreements, soft power, political willpower, partnerships, collaborations and networks, and patient participation. Governance is inseparable from “paradigmatic” framings and cancer must be seen as a human rights issue.

show abstract

Section: The “Messiness” Of Cancer Governancementioning

confidence: 99%

The global challenge of cancer governance

Lunt

2023

World Med & Health Policy

View full text Add to dashboard Cite

show abstract

“…To support access to tafamidis for patients with low incomes, the manufacturer maintains an active PAP where the drug is provided at no cost. Many manufacturers operate similar PAPs to improve access to their innovative prescription therapies 13 .…”

Section: Introductionmentioning

confidence: 99%

Adherence and persistence to tafamidis treatment among Medicare beneficiaries in the presence of a patient assistance program

Chung,

Cantu,

Pankratova

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Tafamidis is the only disease-modifying therapy approved to treat patients in the United States with transthyretin amyloid cardiomyopathy (ATTR-CM), which most commonly affects patients aged ≥ 65 years. The manufacturer operates a patient assistance program (PAP) to support access to tafamidis. This study conducted Privacy Preserving Record Linking (PPRL) using Datavant tokens to match patients across Medicare prescription drug plan (PDP) and PAP databases to evaluate the impact of PAPs on treatment exposure classification, adherence, and persistence determined using Medicare PDP data alone. We found 35% of Medicare PDP patients received tafamidis through the PAP only; 14% through both Medicare PDP and the PAP, and 51% through Medicare PDP only. Adherence and persistence were comparable between these cohorts but underestimated among patients who received ≥ 2 prescriptions through Medicare PDP and ≥ 1 through the PAP when solely using Medicare data versus pooled Medicare and PAP data (modified Medication Possession Ratio: 84% [69% ≥ 80% adherent] vs. 96% [93%]; Proportion of Days Covered: 77% [66% ≥ 80% adherent] vs. 88% [88%]; mean days to discontinuation: 186 vs. 252; total discontinuation: 13% vs. 11%). Cross-database PPRL is a valuable method to build more complete treatment journeys and reduce the risk of exposure misclassification in real-world analyses.

show abstract

“…As a result, a greater portion of the population may go without necessary medications and are more prone to adverse events from poorly controlled disease states. This is especially true for the uninsured population (3). Uncontrolled disease states would be expected to lead to an increase in acute care utilization (i.e., more emergency department visits and hospitalizations) (4).…”

Section: Introductionmentioning

confidence: 99%

Impact of Patient Assistance Programs on Hospital Visits in Patients With Chronic Obstructive Pulmonary Disease or Asthma

Gallman

Huddleston

Ray

et al. 2022

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Background The inability to afford medications can lead to nonadherence and uncontrolled disease states. As a result, patients may require an increase in acute healthcare utilization to control potential complications. Qualifying patients can apply for patient assistance programs (PAPs) through various manufacturers to receive medications at little to no cost. Having consistent access to necessary medications can increase adherence and decrease acute care utilization. The purpose of this study was to evaluate the impact of PAP enrollment on healthcare utilization in patients with asthma or chronic obstructive pulmonary disease (COPD). Objectives The primary objective was to compare the number of ED visits and hospitalizations before and after PAP enrollment. Secondary objectives were the estimated ED and hospitalization costs before and after PAP enrollment. Methods The retrospective, observational cohort study included patients of Piedmont Athens Regional Community Care Clinic who received medications for asthma or COPD through PAPs from January 2018 to March 2019. Results A total of 269 patients were screened, and 56 patients met inclusion criteria. Of these, 28 patients had at least one hospital encounter. Primary objective resulted in cumulative number of ED visits decreased from 54 to 7 ( P < 0.001) and cumulative hospitalizations decreased from 13 to 0 ( P < 0.001). Secondary objective showed patients with at least one hospital encounter had a median cost decrease from $4683 to $0 ( P < 0.001). The median hospital acquisition cost per person decreased from $351 to $0 ( P = 0.002). Conclusion A decrease in use of acute healthcare services was observed after PAP enrollment. This was associated with cost savings for patients and the healthcare system.

show abstract

What is the Evidence for Pharmaceutical Patient Assistance Programs?: A Systematic Review

Cited by 43 publications

References 38 publications

The global challenge of cancer governance

The global challenge of cancer governance

Adherence and persistence to tafamidis treatment among Medicare beneficiaries in the presence of a patient assistance program

Impact of Patient Assistance Programs on Hospital Visits in Patients With Chronic Obstructive Pulmonary Disease or Asthma

Contact Info

Product

Resources

About